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Inhibition of cyclin-dependent kinase 4 as a
potential therapeutic strategy for treatment
of synovial sarcoma
Xiaoyang Li1,2, Nicole A. Seebacher1, Cassandra Garbutt3, Hangzhan Ma1, Peng Gao1, Tao Xiao2,
Francis J. Hornicek1 and Zhenfeng Duan1
Abstract
Synovial sarcoma is a highly aggressive but rare form of soft tissue malignancy that primarily affects the extremities of
the arms or legs, for which current chemotherapeutic agents have not been proven to be very effective. The cyclin-
dependent kinase 4/6-retinoblastoma protein (CDK4/6-Rb) pathway of cell cycle control is known to be aberrant in a
large proportion of cancers. Recently, CDK4 inhibitors have successfully been used pre-clinically for the treatment of
many human cancers, and in 2015, following the success of clinical trials, the FDA approved the first selective CDK4/6
inhibitor, palbociclib, for the treatment of endocrine therapy resistant breast cancers. However, the expression and
therapeutic potential of targeting CDK4 in synovial sarcoma remains unclear. In the present study, we report that CDK4
is highly expressed in human synovial sarcoma, and high CDK4 expressions are associated with poor prognosis in
sarcomas patients and the clinical stage and the TNM grade in synovial sarcoma patients. Knockdown of CDK4 with
specific small interference RNAs inhibits cell proliferation and enhances apoptotic effects in synovial sarcoma cells.
CDK4 inhibitor palbociclib suppresses synovial sarcoma cell proliferation and growth in a dose and time-dependent
manner. Palbociclib also inhibits the CDK4/6-Rb signaling pathway and promotes cell apoptosis without changing
CDK4/6 protein levels, suggesting that palbociclib only represses the hyper-activation, not the expression of CDK4/6.
Flow cytometry analysis reveals that palbociclib induces G1 cell-cycle arrest and apoptotic effects by targeting the
CDK4/6-Rb pathway in synovial sarcoma cells. Furthermore, wound healing assays demonstrate that inhibition of the
CDK4/6-Rb pathway by palbociclib significantly decreases synovial sarcoma cell migration in vitro. Our study highlights
the importance of the CDK4/6-Rb pathway in human synovial sarcoma pathogenesis, and the role of the current
selective CDK4/6 inhibitor, palbociclib, as a potential promising targeted therapeutic agent in the treatment of human
synovial sarcoma.
Introduction
Synovial sarcoma (SS) is a high-grade subtype of soft
tissue sarcoma that occurs mainly in children and young
adults, characterized by the chromosomal translocation
t(X;18) (p11.2; q11.2)1–3. The current treatment for
localized synovial sarcoma is surgery, occasionally with
the combination of additional radiotherapy and che-
motherapy, and the published five-year survival rate varies
from 40% to 60%4,5. However, once the primary disease
advances with pulmonary metastasis and relapse, the
prognosis is poor, even if under the intensive multi-agent
chemotherapy. The limited availability of effective ther-
apeutic measures indicates an urgent clinical need for
novel alternative treatment strategies for patients with
synovial sarcoma.
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Aberrations in cell cycle control is defined as one of the
hallmarks of cancer, and may be a favorable target for the
improvement of new therapeutic options for the treat-
ment of sarcoma6,7. As one of the essential signaling
pathways involved in cell cycle progression, the cyclin-
dependent kinase (CDK) 4/6-retinoblastoma protein (Rb)
pathway (CDK4/6-Rb pathway) is frequently found to be
aberrant in cancer8. CDK4 is one of the serine/threonine
(Ser/Thr) protein kinases that mediates cell cycle pro-
gression through the G1-S phase, in preparation for DNA
synthesis9. The heterodimers formed by CDK4, or its
close homolog CDK6, with D-type cyclins (cyclin D) are
critical for cell cycle progression. In human malignancies,
CDK4 associates with cyclin D and regulates the cell cycle
through hyperphosphorylation and deactivation of the
tumor suppressor retinoblastoma protein (Rb)10,11. Spe-
cifically, in response to pro-proliferative stimuli, cyclin D1
associates with CDK4 and gains access to the nuclear
cyclin D1-CDK4 complex12. These active cyclin D/CDK4
complexes induce the phosphorylation of Rb, and thereby
switch off the tumor suppressing function of Rb13. The
hyperphosphorylated form of Rb is no longer able to bind
with the transcription factor E2F1, leading to cancer cell
cycle progression through activated transcription of var-
ious cell-cycle and anti-apoptotic genes14,15. Activation
and amplification of the cyclin D/CDK4/Rb pathway has
been shown to correlate with uncontrolled tumor cell
growth and proliferation in various types of malignancies,
including in sarcoma16.
CDK4/6 specific inhibitors are the most clinically
advanced type of CDK inhibitor, and notably, a dual
CDK4/6 inhibitor, palbociclib (IBRANCE®). Although
palbociclib was initially developed to target the ATP-
binding site of CDK4, due to the high homologous and
structural similarities between CDK4 and CDK6, palbo-
ciclib also targets CDK6. Palbociclib was the first drug in
this class to receive Food and Drug Administration (FDA)
approval as initial endocrine-based therapy for the treat-
ment of postmenopausal women with hormone receptor
(HR)-positive/human epidermal growth factor receptor 2
(HER2)-negative advanced or metastatic breast cancer
in combination with an aromatase inhibitor, letrozole, or
the selective estrogen receptor downregulator, fulves-
trant17–21. The FDA have since also approved the CDK4/6
inhibitors, ribociclib (KISQALI®) and abemaciclib
(VerzenioTM), for a similar application22. These agents
have also been investigated in other solid tumors, ranging
from melanoma to non-small cell lung cancer23,24.
Although the field of targeted-therapy for carcinomas is
growing rapidly, trials with targeted treatment for rare
cancers, such as sarcomas, remain scarce. Interestingly,
palbociclib is currently registered in a phase II clinical trial
for patients with well-differentiated or dedifferentiated
liposarcoma25,26. A recent study has reported that nuclear
phosphorylated Rb (pRb) expression may be correlated
with a poor prognosis for synovial sarcoma patients, and
put forward for consideration the potential of palbociclib
for patient treatment27. However, as a critical part of the
Cyclin D/CDK4/6/Rb axis, the expression and clinical
significance of CDK4, and the potential mechanism of
targeting CDK4 using the specific inhibitor palbociclib as
a putative therapeutic strategy, remains to be elucidated in
synovial sarcoma. Therefore, in this study, we evaluate the
expression of CDK4 and its therapeutic applications in
human synovial sarcoma, as well as test palbociclib as a
possible treatment for synovial sarcoma.
Results
CDK4 is highly expressed in human synovial sarcoma cell
lines
As demonstrated by western blotting, all these human
synovial sarcoma cell lines exhibit high levels of CDK4
expression (Fig. 1a). We also assessed the expression of
CDK6, cyclin D1, p16INK4A, Bcl-xL, Rb and phosphory-
lated Rb (pRb: Ser795, 780 and 807/811). All of the four
synovial sarcoma cell lines also expressed cyclin D1, pRb,
Rb, and Bcl-xL (Fig. 1a). In contrast, none of these cell
lines expressed p16INK4A. CDK6 was highly expressed in
the SYO-1 and Yamato cell lines, but was undetectable in
the Fuji and Aska cell lines (Fig. 1a). Relative expressions
of CDK4 and CDK6 were compared with β-actin in dif-
ferent synovial sarcoma cell lines (Fig. 1b). To further
assess the subcellular localization of CDK4 in synovial
sarcoma cells, immunofluorescence was performed in
SYO-1 and Fuji cells. The green staining represents the
CDK4 protein, and the red staining represents β-Actin in
the cellular cytoplasm. As shown, CDK4 protein is mostly
localized in the nucleus of synovial sarcoma cells, but with
some localized to the cytoplasm (Fig. 1c).
CDK4 expression levels correlates with the
clinicopathological characteristics of synovial sarcoma
patients
To further validate the clinical significance of CDK4
expression in patients with synovial sarcoma, we tested
the expression levels of CDK4 in a human synovial sar-
coma tissue microarray (TMA) by immunohistochemistry
(IHC), and evaluated the correlation between CDK4
expression and the pathological characteristics of the
synovial sarcoma patients. The expression levels of CDK4
were graded based on the distribution (1 < 10%, 2=
10–25%, 3= 26–50%, 4= 51–75%, 5 > 75%) with score ≥
3 considered high expression.
The IHC results demonstrate that CDK4 immunor-
eactivity is in the nucleus of synovial sarcoma tissue cells
(Fig. 2c). Of the 50 TMA cases of synovial sarcoma, 41
(82.0%) of the tissues express detectable CDK4 expres-
sion. Following evaluation of the clinical history of the
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human synovial sarcoma specimens, no significant cor-
relations are found between the expression of CDK4 and
patient age, gender, tissue type, or tumor location (Sup-
plementary Table 1). However, we find that CDK4
expression significantly correlated with the clinical stage
and TNM grade of the synovial sarcoma (both P < 0.05).
As shown, CDK4 expression is significantly higher in the
higher clinical stages (≥IIB) compared with those in the
lower clinical stages (<IIB) (Fig. 2a). Moreover, CDK4
expression is significantly higher in the higher TNM grade
(≥G2) tissues, compared to the lower TNM grade (<G2)
tissues (Fig. 2b).
Considering the absence of information available about
the patients’ follow-up and clinical outcomes of the
synovial sarcoma TMA, we correlated the CDK4 expres-
sion levels to the clinical prognosis of the various types of
sarcoma TMA. Various types of sarcoma TMA specimens
were also assessed for CDK expression and localization,
demonstrating varying degrees of CDK4 staining in the
cell nucleus (Fig. 3c). Among the tested 59 sarcoma TMA
cases, 52 (88.1%) of the tissues express CDK4. Based on
data from up to 112 months of follow-up, CDK4
expression levels in samples from non-survivors are sig-
nificantly higher than those from survivors (Fig. 3a).
Importantly, Kaplan–Meier survival analysis shows that
the outcomes for patients in the CDK4 high-staining (≥3)
group are worse than for those in the CDK4 low-staining
(<3) group (Fig. 3b). In patients with sarcomas, high
CDK4 expression is associated with shorter overall sur-
vival period vs. low CDK4 expression (P < 0.05). On fur-
ther analysis, significant correlations are not found
between CDK4 expression and sarcoma patient age,
gender, sarcoma type, and tumor location (Supplementary
Table 2).
CDK4 silencing with specific siRNAs suppresses cell
proliferation and enhances apoptotic effect in synovial
sarcoma cell lines
To validate the effect of CDK4/6-Rb pathway in synovial
sarcomas in vitro, we knocked down expression of CDK4
using two CDK4 specific siRNAs. As shown by MTT
assays, after transfection with increasing concentrations of
CDK4 siRNA #SASI_Hs01_00122488 (Fig. 4a, b) and
CDK4 siRNA #SASI_Hs01_00122490 (Suppl. Figures 1A
and 1B) for 5 days, the cell viability is dose-dependently
inhibited in both SYO-1 and Fuji cells, which is not
observed in the nonspecific siRNA transfected cells.
Furthermore, western blotting shows that CDK4 siRNA
transfection significantly reduces CDK4 expression,
whereas the expression of CDK6 remains unchanged. The
Fig. 1 CDK4 is highly expressed in human synovial sarcoma cell lines. a Expression levels of CDK4, CDK6, cyclin D1, p16INK4A, Rb, pRb (Ser795,
780 and 807/811) and Bcl-xL in four synovial sarcoma cell lines SYO-1, Yamato, Fuji, and Aska were detected using Western blotting. b Relative
expressions of CDK4 and CDK6 compared with β-actin in different synovial sarcoma cell lines were figured. c Expression of CDK4 in SYO-1 and Fuji
cells was assessed by immunofluorescence with antibodies to CDK4 and β-Actin. Cells were visualized under a fluorescence microscope after
incubation with Alexa Fluor 488 goat anti-rabbit IgG (green) or Alexa Fluor 594 goat anti-mouse IgG (red), and the images were merged (scale bar,
50 μm)
Li et al. Cell Death and Disease  (2018) 9:446 Page 3 of 14
Official journal of the Cell Death Differentiation Association
expression of p16INK4A is undetectable in SYO-1 and Fuji
cell lines (Fig. 4c, d, Suppl. Figures 1C and 1D). After
transfection with CDK4 siRNA for 48 h, the expression of
pRb is reduced in a dose-dependent manner, whereas the
Rb expression is not significantly changed (Fig. 4c, d,
Suppl. Figures 1C and 1D). A dose-dependent decrease in
the expression of the anti-apoptotic protein, Bcl-xL, is
also observed after transfection with CDK4 siRNA
(Fig. 4c, d, Suppl. Figures 1C and 1D).
Palbociclib inhibits cell proliferation and promotes
apoptosis by targeting the CDK4/6-Rb pathway in human
synovial sarcoma cells
Cell proliferation and growth were determined by MTT
assays in synovial sarcoma SYO-1 and Fuji cells with pal-
bociclib treatment. After exposure to increasing
concentrations of palbociclib for 2, 4, and 6 days, the cell
viability is decreased in a dose-dependent manner in both
SYO-1 (Fig. 5a) and Fuji cells (Fig. 5b). Morphologic changes
are also observed after 2 days of palbociclib exposure. When
treated with increased doses of palbociclib (0, 0.625, 1.25,
2.5, 5, 10 μM) for 48 h, SYO-1 and Fuji cells show pro-
nounced morphologic signs of toxicity, including abnormal
shape and appearance, cellular lysis, and destruction. The
cells begin to show observable signs of toxicity in the form of
cells reduction and abnormal cell morphology when treated
with 1.25 μM palbociclib, and cellular death and other
abnormalities become more pronounced as the drug con-
centration continued to increase up to 10 μM (Fig. 6a).
As shown by western blotting analysis, 2 days of pal-
bociclib exposure significantly decreases the expression of
pRb (Ser795, 780 and 807/811) in a dose-dependent
Fig. 2 CDK4 expression levels correlate to clinicopathological characteristics of synovial sarcoma patients. CDK4 levels in human synovial
sarcoma tissue microarray were determined by immunohistochemistry, and the correlation of CDK4 expression with clinicopathological
characteristics of synovial sarcoma patients was evaluated. a Distribution of CDK4 staining scores among clinical stage≥IIB and clinical stage<IIB
synovial sarcoma tissues. b Distribution of CDK4 staining scores in the synovial sarcoma tissues from TNM grade≥G2 patients and TNM grade<G2
patients. c Representative images of different immunohistochemical staining intensities of CDK4 ( × 200; scale bar=100 µm). On the basis of the
percentage of cells with positive nuclear staining, CDK4 staining patterns were categorized into 6 groups: 0, no nuclear staining; 1+:<10% of positive
cells; 2+, 10–25% of positive cells; 3+, 26–50% of positive cells; 4+, 51–75% of positive cells; 5+,>75% of positive cells
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manner, whereas the expression of Rb is not significantly
changed (Fig. 6b, c). All of the cell line samples show no
p16INK4A expression. A dose-dependent decrease in the
expression of the cell anti-apoptotic protein, Bcl-xL, is
also observed with palbociclib treatment. Notably, wes-
tern blotting shows that the activity of palbociclib had no
influence on the expression of CDK4, CDK6 or cyclin D1,
suggesting that palbociclib only suppresses the activity of
CDK4, but does not change the protein expression
(Fig. 6b, c).
Inhibition of CDK4/6-Rb pathway with palbociclib induces
human synovial sarcoma cell cycle arrest and cell
apoptosis
Due to high concentrations of palbociclib resulting in
pronounced cell death, we used a 1 µM for assessing the
cell cycle. After 1 µM of palbociclib treatment for
24 h, a significant G1 cell-cycle arrest accompanied
by a reduction in the fraction of cells in S phase is
observed in both SYO-1 and Fuji cells (both P < 0.05),
compared with the non-treated control (Fig. 5c, d).
This suggests that CDK4/6-Rb inhibition, induced
by palbociclib, is able to promote G1 cell-cycle
arrest and inhibit DNA synthesis in synovial sarcoma
cells. The cell apoptosis analysis demonstrates increased
apoptosis rates in both SYO-1 and Fuji cells after palbo-
ciclib exposure for 24 h, as compared with the control
group (Suppl. Figures 2A and 2B). Collectively, these
results indicate that reduced synovial sarcoma cell pro-
liferation by inhibition of CDK4/6-Rb pathway is asso-
ciated with induction of cell cycle arrest and cell
apoptosis.
Fig. 3 CDK4 expression levels associate with clinicopathological characteristics of various sarcomas patients. CDK4 levels in human various
sarcomas tissue microarray were determined by immunohistochemistry, and the relationship between CDK4 expressions and clinicopathological
characteristics of various sarcomas patients was analyzed. a Distribution of CDK4 staining scores in the synovial sarcoma tissue samples from survival
and non-survival patients. b Kaplan–Meier survival curve of sarcoma patients with CDK4 high staining (≥3) or low staining (<3). c Representative
images of different immunohistochemical staining intensities of CDK4 (×200; scale bar:100 µm). On the basis of the percentage of cells with positive
nuclear staining, CDK4 staining patterns were categorized into 6 groups: 0, no nuclear staining; 1+:<10% of positive cells; 2+, 10–25% of positive
cells; 3+, 26–50% of positive cells; 4+, 51–75% of positive cells; 5+, >75% of positive cells
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Inhibition of the CDK4/6-Rb pathway with palbociclib
reduces human synovial sarcoma cell migration in vitro
The wound healing assay was performed in SYO-1 and
Fuji cells after palbociclib treatment. After exposure to 1
µM of palbociclib for 24, 48, and 72 h, the cell migration
activities are significantly and time-dependently sup-
pressed in both SYO-1 and Fuji cells, as compared with
the palbociclib-free control groups (P < 0.01) (Fig. 7).
Discussion
The CDK4/6-Rb pathway is a fundamental driver for
cell cycle control and regulation of cellular apoptosis28,29,
and could serve as a promising therapeutic target in
various human malignancies30–34. Since its activity plays a
crucial role in the proliferation and progression of cancer,
pharmacological inhibitors targeting the CDK4/6 pathway
have emerged as an attractive approach in oncology35,36.
In the current study, we explore the expression and
function of the CDK4/6-Rb pathway in synovial sarcomas,
and investigate the therapeutic potential of the selective
CDK4 inhibitor, palbociclib, in vitro.
We first analyzed the expression levels of CDK4 in
synovial sarcoma cell lines and found that CDK4 was
highly expressed in all the human synovial sarcoma cell
lines, and it was found to be localized to the nucleus by
immunofluorescence staining. While previous studies
have assessed the expression of CDK4 in some sarcoma
types, including liposarcoma and Ewing’s sarcoma37,38,
none of these studies have assessed the expression of
CDK4 in synovial sarcoma. A study by Vlenterie et al,
2016, has analyzed the expression of cyclin D1 and
nuclear phosphor-Rb in 43 synovial sarcoma tissue sam-
ples, however, this study did not characterize the rela-
tionship between the level of CDK4 expression and the
clinical characteristics of the patients27. In our study,
synovial sarcoma TMAs determined by IHC showed that
CDK4 expression was observed in most of the tested
sarcoma tissue samples. This suggests CDK4 might have
an important role in the pathogenesis of synovial sarcoma.
Further studies explored the relationship between CDK4
expression and clinicopathological characteristics using a
TMA containing 50 synovial sarcoma cases with clinical
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Fig. 4 CDK4/6-Rb pathway inhibition induced by CDK4 specific siRNA (#SASI_Hs01_00122488) decreases cell proliferation and promotes
apoptosis in synovial sarcoma cells. Human synovial sarcoma SYO-1 and Fuji cells were transfected with increasing concentrations of
CDK4 specific siRNA (#SASI_Hs01_00122488) or nonspecific siRNA, and cell proliferation and growth was determined subsequently. a, b Cell viability
was determined by MTT assay after siRNA transfection for 5 days. c, d The respective proteins of CDK4/6-Rb-apoptosis pathway in cells were
examined by Western blotting after 48 h of siRNA transfection. **P < 0.01 compared with the cell only group
Li et al. Cell Death and Disease  (2018) 9:446 Page 6 of 14
Official journal of the Cell Death Differentiation Association
information, and a TMA containing 59 various sarcoma
cases with up to 112 months of follow-up data. Our
results showed that CDK4 expression significantly corre-
lated with a higher clinical stage and a higher TNM grade
of synovial sarcoma patients, and a worse clinical prog-
nosis of sarcoma patients. A previous study of lipo-
sarcoma supports that the overexpression of CDK4 is
correlated to a poorer prognosis of patients39. A knock-
down of CDK4 in fusion-gene positive rhabdomyo-
sarcoma cells has also been shown to abrogate
transformation and proliferation via G1-phase cell-cycle
arrest, demonstrating that CDK4 is also essential for
sarcoma cell survival and growth40. More recently,
amplification and over-activation of the CDK4/Rb path-
way has been found in another sarcoma type, chordoma41.
Altogether, these results verify the expression of CDK4 in
synovial sarcomas and highlight its important role in
sarcomas, including synovial sarcoma.
In contrast to the previous study that only investigated
cyclin D1 and pRb levels following palbociclib treat-
ment27, we specifically knocked down CDK4 expression
with CDK4 siRNAs to investigate the role of CDK4 in
synovial sarcoma cell growth and proliferation. The result
showed that CDK4 inhibition by siRNA decreased syno-
vial sarcoma cell proliferation and growth in a dose-
dependent manner. We further suppressed the expression
of CDK4 in synovial sarcoma cells using the clinically
approved CDK4 inhibitor, palbociclib, and explored
changes to the cellular phenotypic. Consistently, our
findings demonstrated that CDK4 inhibition by palboci-
clib reduced synovial sarcoma cell proliferation and
growth dose-dependently. We demonstrated that
Palbocilcib 0μM Palbocilcib 1μM
Fuji
Palbocilcib 0μM Palbocilcib 1μM
SYO-1C
D
**
** *
**
** **
BA
Fig. 5 Inhibition of CDK4/6-Rb pathway by palbociclib decreases cell proliferation and induces cell cycle arrest in human synovial
sarcomas. Human synovial sarcoma SYO-1 and Fuji cells were treated with increasing concentrations of palbociclib for the indicated time, and cell
proliferation and growth was determined subsequently. a, b Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and
6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis. Representative
images of cell cycle distribution in SYO-1 (c) and Fuji (d) cells with or without palbociclib treatment. Cell numbers in different cell cycle phases were
counted. Different cell cycle phase rates were also analyzed. *P < 0.05, **P < 0.01 compared with the cell only group
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palbociclib was acting through inhibition of CDK4/6
activity, not by reducing protein expression. These find-
ings collectively suggest that CDK4 plays a crucial role in
promoting synovial sarcoma proliferation and growth.
As a fundamental cell division modulator, CDK4 func-
tions mainly through activation, by phosphorylation, of
the retinoblastoma tumor suppressor, inducing G1 cell
cycle arrest in tumor cells42. In response to mitogenic
signals, CDK4 combines with cyclin D1 and transfers into
the nucleus to form the active cyclin D1–CDK4 complex
and then phosphorylates Rb into pRb. Our immuno-
fluorescence straining showed that CDK4 expression was
observed both in the cytoplasm and in the nucleus of
SYO-1 and Fuji cells, but mostly localized in the nucleus.
It has been suggested that in proliferating cells, during G1
phase, cyclin D1 accumulates in the nucleus and triggers
the active cyclin D1-CDK4 complex formation43. This
leads to release of the E2F transcription factor and acti-
vation of downstream target genes, promoting cell cycle
progression and ultimately cell proliferation and growth44.
Notably, the cyclin D/CDK4/Rb pathway is universally
disrupted in human cancer45,46. Thus, we explored
changes occurring in proteins of the cyclin D/CDK4/Rb
pathway after CDK4 inhibition. We found that both the
CDK4 specific siRNA and palbociclib suppressed down-
stream Rb phosphorylation and also reduced expression
of the cell-survival protein Bcl-xL, in a dose-dependent
manner. Bcl-xL is a member in Bcl-2 family, which is
known to suppress downstream activators of apoptosis47.
Interestingly, synovial sarcomas are known to have high
levels of Bcl-2 compared to other soft tissue sarcomas48.
Notably, while palbociclib acted only to inhibit CDK4
activity, with no changes to protein expression, it also
effectively downregulated pRb and Bcl-xL expression.
To demonstrate the potential mechanisms underlying
CDK4 inhibition caused by palbociclib treatment on
synovial sarcoma cell growth, flow cytometry analysis was
used to assess the cell cycle and apoptosis in human
synovial sarcoma cells following treatment with palboci-
clib. The results revealed that CDK4 inhibition dramati-
cally induced cell cycle arrest in G1 phase in synovial
sarcoma cells after palbociclib treatment. Cell apoptosis
determination simultaneously revealed that CDK4 inhi-
bition dramatically induced cell apoptosis in synovial
sarcoma cells. Hence, these findings confirmed that CDK4
inhibition, triggered by palbociclib, could decrease
Fig. 6 Inhibition of CDK4/6-Rb pathway by palbociclib alters phosphorylation of Rb and promotes apoptosis in human synovial sarcomas.
a Human synovial sarcoma SYO-1 and Fuji cells were treated with increasing concentrations of palbociclib for the indicated time, and the
morphologic changes of cells were observed by microscopy after 2 days of palbociclib treatment (scale bar, 50 μm). The expression of respective
proteins in CDK4/6-Rb pathway and apoptosis in SYO-1 (b) and Fuji (c) cells was examined by western blotting after 3 days of palbociclib treatment
Li et al. Cell Death and Disease  (2018) 9:446 Page 8 of 14
Official journal of the Cell Death Differentiation Association
synovial sarcoma cell proliferation and growth via
induction of cell apoptosis via arresting the cell cycle in
G1 phase.
p16INK4A, encoded by cyclin-dependent kinase inhibitor
2A (CDKN2A) tumor suppressor gene, is one of the first
genes noted to be silenced epigenetically in human can-
cers49. Specific somatic loss of p16INK4A through point
mutations or small deletions, and silencing of p16INK4A
through promoter methylation, have been reported at
high frequency in many human cancers50,51. Restriction of
cell cycle progression occurs through inhibition of the
activity of CDK4 by p16INK4A 37. A deletion of p16INK4A
causes altered activity of CDK4, leading to hyperpho-
sphorylation of Rb and aberrant regulation of the cell
cycle52,53. Preclinical data indicates that cancers with a
loss in p16INK4A may still be sensitive to CDK4 inhibi-
tion54,55. Palbociclib has been shown to inhibit the growth
of doxorubicin-resistant Ewing’s sarcoma patient-derived
orthotopic xenografts in vivo, with a p16INK4A-deletion56.
Specific orthotopic mouse models developed from sar-
coma patients, may help in the development of indivi-
dualized therapeutics to precisely target patient specific
sarcomas57–61. In synovial sarcoma, the deletion of
p16INK4A is also a frequent genetic event62. This study
shows that synovial sarcoma cells, with a loss in P16INK4A,
are sensitive to palbociclib treatment, indicating that
palbociclib may be a potential therapeutic drug to treat
synovial sarcoma.
0 h
Palbociclib
24 h
48 h
72 h
Cell only ijuF1-OYS
0 h
Palbociclib
24 h
48 h
72 h
Cell only
A B
C D
Fig. 7 Inhibition of the CDK4/6-Rb pathway by palbociclib reduced human synovial sarcoma cell migration in vitro. After exposure to 1 µM
of palbociclib for the indicated time, the cell migration of SYO-1 and Fuji cells was determined by wound healing assays. a Representative images of
SYO-1 cell migration after palbociclib treatment for 24, 48, and 72 h (scale bar, 50 μm). b Representative images of Fuji cell migration after palbociclib
treatment for 24, 48, and 72 h (scale bar, 50 μm). c Cell migration distance of SYO-1 cells was measured after palbociclib treatment. d Cell migration
distance of Fuji cells was measured after palbociclib treatment. ***P < 0.001 compared with the cell only group
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The development of tumor cell invasion and metastasis
is, largely, responsible for the mortality and morbidity of
cancer63. TMA analysis showed that the overexpression of
CDK4 was related to higher clinical stages and higher
TNM grades in synovial sarcomas and this correlated with
a poorer patient prognosis in various sarcomas, indicating
that CDK4 might be necessary for tumor metastasis. The
course of metastasis from the primary tumor sites to
distant other organs is of principal importance in the
prognosis of cancer patients63. In synovial sarcoma, a high
incidence of late metastasis occurs in about 50% of all
cases, which significantly impacts the mortality and
reduces patient survival outcomes64,65. We then further
analyzed the effect of CDK4 inhibition on synovial sar-
coma cell migration in vitro. Synovial sarcoma cells
treated with non-lethal doses of palbociclib unveiled that
CDK4 inhibition reduced synovial sarcoma cell migration,
suggesting that CDK4 might be a promotor to synovial
sarcoma metastasis, which is the main obstacle in the
treatment of synovial sarcoma.
Taken together, our current study demonstrates that
CDK4 is highly expressed in synovial sarcomas. Over-
expression of CDK4 correlates with higher clinical stages
and higher TNM grades in synovial sarcomas and poor
survival outcomes of sarcoma patients. CDK4 inhibition
decreases synovial sarcoma cell proliferation and growth
through apoptosis induction via cell cycle arrest. These
findings, together with the current clinical application of
palbociclib for other malignancies, highlight CDK4 as a
potential therapeutic target and palbociclib as a promising
anti-cancer agent for synovial sarcoma treatment.
Materials and methods
Cell lines and cell culture
The human synovial sarcoma cell lines SYO-1 and Fuji
were kindly provided by Dr. Akira Kawai (National Can-
cer Center Hospital, Tokyo, Japan) and Dr. Kazuo Naga-
shima (Hokkaido University School of Medicine,
Hokkaido, Japan), respectively66,67. The human synovial
sarcoma cell lines Yamato-SS and Aska-SS were gener-
ously provided by Dr. Kazuyuki Itoh (Osaka Medical
Center for Cancer and Cardiovascular Diseases, Osaka,
Japan)68. All synovial sarcoma cell lines were cultured in
RPMI-1640 (Life Technologies, Grand Island, NY) com-
plete media supplemented with 10% fetal bovine serum
(GIBCO, Grand Island, NY, USA), 100 U/mL penicillin G,
and 100 μg/mL streptomycin (Life Technologies, Carls-
bad, CA). All cells were incubated in a humidified 5%
CO2-95% air atmosphere at 37 °C.
Immunofluorescence assay
For immunostaining of cultured synovial sarcoma cells,
SYO-1 and Fuji cells were grown in 6-well plates for
2 days and fixed with 3.7% paraformaldehyde for 15min,
followed by permeabilization with ice-cold methanol and
blocked with 1% bovine serum albumin (BSA). The cells
were then incubated with the CDK4 primary antibody
(1:200 dilution, #12790, Cell Signaling Technology, Bev-
erly, MA, USA) and β-Actin (1:200 dilution, #sc-47778,
Santa Cruz Biotechnology, Dallas, TX, USA) at 4 °C
overnight, followed by incubation with Alexa Fluor 488
(Green) conjugated goat anti-rabbit antibody and Alexa
Fluor 594 (Red) goat anti-mouse antibody (Invitrogen,
Carlsbad, CA, USA) for 1 h. Finally, cells were imaged on
a Nikon Eclipse Ti-U fluorescence microscope (Diag-
nostic Instruments Inc., NY, USA) equipped with a SPOT
RT™ digital camera.
Immunohistochemistry analysis of human tissue
microarray (TMA)
The expression of CDK4 in the human tissue micro-
array was determined by immunohistochemistry assay
(Paraffin) according to the manufacturer’s instructions
(Cell Signaling Technology, Beverly, MA, USA). The
synovial sarcoma TMA (US Biomax, Inc., Rockville, MD,
USA) contains 50 cases/100 cores with histopathologic
data, including age, gender, tissue type, tumor location,
clinical stage, TNM grade, and pathology type. The
synovial sarcoma TMA information is available at the
website (http://www.biomax.us/tissue-arrays/Soft_Tissue/
SS1001). The various sarcomas TMAs were purchased
from SuperBioChips Laboratories (Seoul, South Korea)
and contain 59 paraffin-embedded tumor specimens from
59 individual sarcoma patients. Clinicopathological
information including age, gender, sarcoma type, tumor
location, the follow-up time and prognostic outcome can
be obtained from the website (http://www.tissue-array.
com). Hematoxylin and Eosin stained tissue array slides
were made available online by the manufacturers.
Briefly, the two 5 μm paraffin-embedded TMA slides
were baked for 1 h at 60 °C, deparaffinized in xylene three
times for 10min each, and then transferred through
graded ethanol (100 and 95%) twice for rehydration, 10
min each. After heat-induced epitope retrieval, the
endogenous peroxidase was quenched by 3% hydrogen
peroxide. Following blocking by normal goat serum for 1
h at room temperature, the two slides were incubated
with rabbit polyclonal antibody to human CDK4 (#12790,
1:500 dilution, Cell Signaling Technology, Beverly, MA,
USA) at 4 °C overnight in a humidified chamber. Subse-
quently, bound antibody on the array was detected by
SignalStain® Boost Detection Reagent (Cell Signaling
Technology, Beverly, MA, USA) and SignalStain® DAB
(Cell Signaling Technology, Beverly, MA, USA). The
nuclei of synovial sarcoma cells were counterstained with
hematoxylin QS (Vector Laboratories, Burlingame, CA,
USA) to improve images. Finally, the section was moun-
ted with VectaMount AQ (Vector Laboratories,
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Burlingame, CA, USA) for long-term preservation. The
TMA slides were also stained in the absence of CDK4
antibody to evaluate nonspecific secondary antibody
reactions. The slide was imaged using an Olympus
microscope (BX51, Olympus, PA, USA).
Immunostaining of the whole slide areas were viewed
and scored separately by three independent pathologists
who were blinded to tumor characteristics and core case
details. The expression level of CDK4 was evaluated
according to the percentage of cells with positive nuclear
staining. Staining patterns were categorized on a semi-
quantitative scale from 0–5+ , as follows: 0, no nuclear
staining; 1+ , < 10% of positive cells; 2+ , 10–25% of
positive cells; 3+ , 26–50% of positive cells; 4+ , 51–75%
of positive cells; 5+ , > 75% of positive cells. Tumors with
a staining score of ≥ 3 were designated as high CDK4
expression and < 3 were designated as low CDK4
expression.
Synthetic CDK4 siRNA transfection and drug treatment
CDK4 knockdown was performed by CDK4 specific
siRNA transfection in synovial sarcoma cells. The
human nonspecific siRNA and CDK4 siRNAs
(#SASI_Hs01_00122488, NM_000075.2, 5′-CUCUUAU-
CUACAUAAGGAU-3′ and #SASI_Hs01_00122490,
NM_000075.2, 5′-CACUUACACCCGUGGUUGU-3′)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). The nonspecific siRNA oligonucleotides were used
as negative controls. Increasing concentrations (0, 10, 30,
and 60 nM) of CDK4 siRNAs or nonspecific siRNA (60
nM) were transfected into cells using Lipofectamine®
RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. After 48 h
for western blotting or 5 days for MTT assay, transfected
cells were subjected to subsequent analysis.
CDK4 inhibition in synovial sarcoma cells was carried
out by palbociclib treatment. Palbociclib (PD-0332991)
HCl (#S1116, Selleck Chemicals, Houston, TX, USA) is a
highly selective inhibitor of CDK4/6 activity. SYO-1 and
Fuji cells were grown on 96-well plates for cell prolifera-
tion assays, 6-well plates for wound healing assays, or 12-
well plates for western blotting analysis, and incubated
with various concentrations of palbociclib, followed by
subsequent experiments.
Cell proliferation assay
SYO-1 and Fuji cells were seeded into 96-well plates at a
density of 4 × 103 cells per well, and treatments were
performed for 5 days after CDK4 siRNA transfection or 2,
4, and 6 days after palbociclib treatment, the cell viability
of SYO-1 and Fuji cells was determined using MTT
assays. Briefly, at the end of cell treatment, 20 μL of MTT
(5 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was added
to each well and the 96-well plates were incubated at
37 °C in a 5% CO2-95% air humidified atmosphere
for 4 h. Finally, the resulting formazan product
was dissolved with 100 μL of acid isopropanol and the
absorbance at a wavelength of 490 nm (A490) was mea-
sured on a SpectraMax Microplate® Spectrophotometer
(Molecular Devices LLC, Sunnyvale, CA, USA). In all
experiments, the MTT assays were conducted in tripli-
cate. Meanwhile, light microscope images of the mor-
phological changes of the SYO-1 and Fuji cells were
obtained by a Zeiss microscope (Carl Zeiss, Inc., Ober-
kochen, Germany) with an attached Nikon D40 digital
camera (Diagnostic Instruments Inc., NY, USA) equipped
with a Zen Imaging software after increasing concentra-
tions (0, 0.625, 1.25, 2.5, 5, 10 µM) of palbociclib treat-
ment for 48 h.
Protein preparation and Western blotting
Protein lysates were extracted from SYO-1 and Fuji cells
with 1× RIPA lysis buffer (Upstate Biotechnology, Char-
lottesville, VA, USA) supplemented with complete pro-
tease inhibitor cocktail tablets (Roche Applied Science,
Indianapolis, IN, USA). The concentrations of the protein
lysates were determined by DCTM protein assay reagents
(BIO-RAD, Hercules, CA, USA) with a Beckman spec-
trophotometer (Beckman Instruments, Inc., Indianapolis,
IN, USA). Equal concentrations of denatured proteins
were separated by NuPAGE® 4–12% Bis-Tris Gel (Invi-
trogen, Carlsbad, CA, USA), and then transferred to
nitrocellulose membranes (BIO-RAD, Hercules, CA,
USA). After blocking with 5% non-fat milk for 1 h, the
membranes were incubated with rabbit monoclonal
antibodies to human CDK4, CDK6, cyclin D1, p16INK4A,
pRb (Ser795, 780 and 807/811), and Bcl-xL (1:1000 dilu-
tion, Cell Signaling Technology, Beverly, MA, USA),
mouse monoclonal antibodies to human Rb (1:1000
dilution, Cell Signaling Technology, Beverly, MA, USA)
and β-actin (1:2000 dilution, Santa Cruz Biotechnology,
Dallas, TX, USA) at 4 °C overnight. Following primary
antibody incubation, the membranes were washed with
TBST for 3 times, 5 min every time, and Goat anti-rabbit
IRDye® 800CW (926-32211, 1:5000 dilution, Li-COR
Biosciences, NE, USA) or Goat anti-mouse IRDye®
680LT secondary antibody (926-68020, 1:10000 dilution,
Li-COR Biosciences, NE, USA) were added, respectively.
After incubation at room temperature for 2 h, the bands
were detected using Odyssey Infrared Fluorescent Wes-
tern Blots Imaging System from Li-COR Bioscience
(Lincoln, NE, USA). Quantification of Western blotting
results was analyzed using Odyssey software 3.0 (Li-COR
Bioscience, Lincoln, NE, USA).
Flow cytometry analysis
The cell cycle status of SYO-1 and Fuji cells were ana-
lyzed by flow cytometry after 24 h of palbociclib
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treatment. SYO-1 and Fuji cells were collected and fixed
in 70% ethanol at 4 °C overnight, followed by incubation
with RNase A (100ug/mL, Thermo Scientific, Waltham,
MA, USA) at 37 °C for 30min and stained with Propidium
Iodide (50ug/mL, Sigma-Aldrich, St. Louis, MO, USA) for
an additional 30 min. The DNA content was determined
by flow cytometry (FACSCanto II, BD, NJ, USA) and the
population of cells in each phase of the cell cycle analyzed
with the MultiCycle software (Phoenix Flow Systems, CA,
USA).
Cell apoptosis in SYO-1 and Fuji cells were analyzed by
flow cytometry after 24 h of palbociclib treatment. For cell
apoptosis analysis, the cells were collected by trypsiniza-
tion and resuspended in annexin-binding buffer, followed
by staining with FITC annexin V and Propidium Iodide
(Invitrogen, NY, USA) for 30 min, and then subjected to
flow cytometry analysis.
Cell migration assay
Cell migration activity was detected by wound
healing assays. SYO-1 and Fuji cells were seeded into
6-well plates at a density of 4 × 105 cells per well and
incubated overnight. After cells reached 100% confluency,
the adherent cell layer was wounded by scraping
three parallel lines with a sterile 10 μL tip, and 1 µM of
palbociclib was immediately added into the cell medium
for an additional starved incubation with low-serum
medium containing 2% FBS, since serum starving is the
most common non-pharmaceutical method for mini-
mizing proliferation in wound healing assays69,70.
Wounds were observed at 0, 24, 48 and 72 h after pal-
bociclib treatment. The wounded cells within each well
were photographed each time point under a Zeiss
microscope (Carl Zeiss, Inc., Oberkochen, Germany) with
an attached Nikon D40 digital camera (Diagnostic
Instruments Inc., NY, USA) equipped with Nikon Camera
Control Pro 2 Imaging software (Diagnostic Instruments
Inc., NY, USA). The wound width was evaluated by
measuring the distance between the two edges of the
scratch at five sites in each image. Cell migration was
determined using the following formula: Percentage of
wound healing (%)=(wound width at the 0 h time point
−wound width at the observed time point) / wound width
at the 0 h time point × 100%.
Statistical analysis
Statistical analysis was performed using the GraphPad
PRISM 5 software (GraphPad Software, San Diego, CA,
USA). Data are expressed as mean±SD. Student’s t-test
was used to determine the statistical significance of dif-
ferences between groups. Survival analysis was assessed
using the Kaplan-Meier method, and significance was
determined by the log-rank test. A P value of ≤0.05 was
considered statistically significant.
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